Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
102 hedge funds and large institutions have $322M invested in Aerie Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 51 increasing their positions, 23 reducing their positions, and 23 closing their positions.
122% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 23
75% more call options, than puts
Call options by funds: $1.43M | Put options by funds: $816K
12% less funds holding
Funds holding: 116 → 102 (-14)
46% less capital invested
Capital invested by funds: $596M → $322M (-$274M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
52% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$28.9M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$11.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.33M |
| 4 |
Goldman Sachs
New York
|
+$6.31M |
| 5 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$14.2M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$11.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.42M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$4.37M |
| 5 |
RCMC
Rubric Capital Management (Connecticut)
Stamford,
Connecticut
|
-$2.99M |
AERI Hedge Fund Activity: Q1 2016 in Review
102 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q1 2016, worth a combined $322M — down 46% from $596M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of AERI and 11 opened new positions — a net loss of 12 holders — while 23 trimmed existing stakes and 51 added.
The largest buyer was Deerfield Management, adding an estimated $28.9M. The largest seller was Millennium Management, exiting entirely with an estimated $14.2M sold.
- 102 institutional investors held Aerie Pharmaceuticals (AERI) as of Q1 2016, down from 116 in Q4 2015.
- Funds reported $322M of Aerie Pharmaceuticals stock for Q1 2016, down 46% quarter-over-quarter.
- 11 funds opened new Aerie Pharmaceuticals positions in Q1 2016 and 23 closed out, a net change of -12 holders.
- The largest Aerie Pharmaceuticals buyer in Q1 2016 was Deerfield Management, an estimated $28.9M added.
- The largest Aerie Pharmaceuticals seller in Q1 2016 was Millennium Management, an estimated $14.2M sold.
Based on aggregated 13F filings for Q1 2016.